A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
Detailed Phase 3 results for intismeran autogene plus pembrolizumab showed reductions in recurrence and distant metastasis endpoints versus pembrolizumab alone.
TL;DR
- Moderna and Merck reported detailed INTerpath-001 results for intismeran autogene combined with pembrolizumab in patients with resected stage IIB-IV melanoma.
- The companies reported a 42% reduction in recurrence or death risk and a 38% reduction in distant metastasis or death risk compared with pembrolizumab alone.
- Overall survival and regulatory review remain open, and the findings do not establish an approval decision or a treatment recommendation.
Moderna and Merck released detailed results from INTerpath-001, a Phase 3 study of intismeran autogene, an individualized mRNA-based therapy, given with pembrolizumab after surgery for stage IIB-IV melanoma. The comparison group received pembrolizumab alone. [1][2] [1] [2]
The trial enrolled more than 1,100 patients, and the companies had previously announced that it met its recurrence-free survival and distant metastasis-free survival endpoints. The newly reported results supplied the numerical detail ahead of a planned presentation at the European Society for Medical Oncology meeting. [1][2][3] [1] [2] [3]
The reported combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% versus pembrolizumab alone. Reuters reported that the analysis covered the first two years after treatment; AP also reported that the combination was tested as an addition to standard follow-up immunotherapy. [1][2] [1] [2]
The reported endpoints do not resolve overall survival, longer-term outcomes, or the eventual regulatory decision. These results concern a specific post-surgical melanoma population and investigational combination; further follow-up and regulator review remain necessary. [1][3] [1] [3]
Why it matters
The detailed readout moves the program beyond a topline announcement by quantifying recurrence and distant-metastasis outcomes in a late-stage trial. Whether those endpoint gains translate into longer survival, broader use, or regulatory approval remains unsettled.
Editor's note
Results cross-checked across AP, Reuters, and STAT. No clinical advice; overall survival and regulatory status remain open.